Declining childhood and adolescent cancer mortality

To evaluate whether progress continues in identifying more effective treatments for children and adolescents with cancer, the authors examined both overall and disease‐specific childhood cancer mortality rates for the United States, focusing on data from 2000 to 2010.

[1]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[2]  J. Reynolds,et al.  All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 ) , 2012 .

[3]  E. Feuer,et al.  Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.

[4]  A. Bleyer,et al.  The challenges of clinical trials for adolescents and young adults with cancer , 2008, Pediatric blood & cancer.

[5]  C. Stiller,et al.  Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[7]  G. Reifenberger,et al.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. , 2008, The Journal of clinical investigation.

[8]  Rob Pieters,et al.  Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. , 2013, The Lancet. Oncology.

[9]  N. Heerema,et al.  Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Biegel,et al.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.

[11]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[12]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[13]  N. Heerema,et al.  Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031. , 2007 .

[14]  R. Orentas,et al.  Immunotherapy Targets in Pediatric Cancer , 2011, Front. Oncol..

[15]  J. Gastier-Foster,et al.  Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.

[16]  N. Heerema,et al.  Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Grupp,et al.  The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer , 2012, Clinical Cancer Research.

[18]  M. Lim,et al.  Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. , 2012 .

[19]  H. Kantarjian,et al.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Hyune-Ju Kim,et al.  Kim H-J, Fay MP, Feuer EJ, Midthune DN, ‘ Permutation tests for joinpoint regression with applications to cancer rates’. Statistics in Medicine 2000 19:335–351 , 2001 .

[21]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[22]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[24]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[25]  N. Heerema,et al.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.

[26]  C. Mackall,et al.  Highlights of the Second International Conference on “Immunotherapy in Pediatric Oncology” , 2011, Pediatric hematology and oncology.

[27]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Connor,et al.  “Creating Hope” and Other Incentives for Drug Development for Children , 2011, Science Translational Medicine.

[29]  R. Larson,et al.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.

[30]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[31]  M. Loh,et al.  Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.